Protein Kinase C Alpha Location and the Expression of Phospho-MEK and MDR1 in Hepatitis Virus-Related Hepatocellular Carcinoma Biopsies

Chien-Chung Lin¹, ², Jin-Ming Hwang³, Min-Ting Tsai⁴, Wei-Wen Su⁴, Li-Mien Chen⁵, Tung-Yuan Lai⁶, Hsi-Hsien Hsu⁷, Shiow-Kang Yen¹, *, Chih-Yang Huang⁸, ⁹, ¹⁰, *, and Jer-Yuh Liu¹¹, ¹², *

¹Department of Materials and Science and Engineering, National Chung Hsing University, Taichung
²Orthopaedic Department, Armed Forces General Hospital, Taichung
³School of Applied Chemistry, Chung-Shan Medical University, Taichung
⁴Division of Hepatogastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua
⁵Departments of Internal Medicine, Armed Force Taichung General Hospital, Taichung
⁶School of Post-Baccalaureate Chinese Medicine, China Medical University, Taichung
⁷Division of Colorectal Surgery, Mackay Memorial Hospital, Taipei
⁸Graduate Institute of Chinese Medical Science, China Medical University, Taichung
⁹Graduate Institute of Basic Medical Science, China Medical University, Taichung
¹⁰Department of Health and Nutrition Biotechnology, Asia University, Taichung
¹¹Center for Molecular Medicine, China Medical University Hospital, Taichung
¹²Graduate Institute of Cancer Biology, China Medical University, Taichung

Taiwan, Republic of China

Abstract

The purpose of this study was to elucidate the function of protein kinase C (PKC) α in human hepatocellular carcinoma (HCC). Histopathoimmunologic techniques were used to determine the localization and/or expression of PKC α, phospho-mitogen-activated protein kinase (MEK) and multidrug resistance 1 (MDR1) in HCC biopsies. Expression of PKC α, phospho-MEK and MDR1 was significantly increased in the region of HCC location compared with the non-tumor location. The HCC tissues were classified as cytosolic type, where PKC α was deposited in the cytoplasm in > 50% of cells, or membranous type for others. The results showed that the higher expression levels of phospho-MEK and MDR1 in HCC location were significantly associated with those patients whose cells were of the membranous type. Moreover, the expression of MDR1 in HCC location was also significantly associated with the phospho-MEK, and was significantly higher in the patients with anti-HCV negative readings. The results indicate that elevated expression of MDR1 in HCC patients with non-HCV infection may be mediated through PKC signaling pathway.

Key Words: hepatitis C virus, hepatocellular carcinoma, MDR1, phospho-MEK, protein kinase C alpha
Expression of MEK and MDR1 in Human HCC

Introduction

Chronic hepatitis due to hepatitis B virus (HBV) and/or hepatitis C virus (HCV) is a well-documented major risk factor of hepatocellular carcinoma (HCC) (16). HBV is a partially double-stranded DNA virus with a genome size of about 10 kb encoding a number of structural (core, E1, E2, and p7) and nonstructural (NS2, NS3, NS4A, NS4B, and NS5B) proteins (9, 14). The HCV core protein has the strongest influence on NF-κB, AP-1- and SRE-associated pathways (24). Activation of these signaling pathways by HBx or HCV core proteins has been reported to play an important role in the progression of liver injury, cirrhosis and HCC (3, 13, 14, 28, 39).

HBx uses a complex signal transduction pathway for transactivation in carcinogenesis. An increase in the endogenous protein kinase C (PKC) activator sn-1,2-diacylglycerol and the subsequent activation of PKC gives rise to the activation of the transcription factor AP-1 (Jun-Fos) (25). HBx activates PKC differently from the ras oncogene product or phorbol ester in that it does not lead to rapid down-regulation of the enzyme subsequent to the activation (30). Since HBx is more active than the hepatitis B virus surface antigen (HBsAg) in HCC (12, 38), it may be an important factor for PKC activation in the progressive malignancy of HCC. Moreover, nonstructural protein 3 (NS3) of HCV may inhibit the TPA-induced redistribution of PKCα or PKCβ (4). These findings suggest that PKC plays an important role in hepatocarcinogenesis.

PKC is a lipid-regulated and calcium-dependent protein kinase that plays an important role in the control of cell growth and differentiation (33). PKC has 10 isoforms with different distribution patterns, structures and functions in various tissues (31, 32). Although elevation in PKC activity has been demonstrated in breast tumors (34), pituitary tumors (1) and malignant gliomas (11), reduction of PKC activity has also been determined in colonic carcinoma (26, 27) and HCC (6). We have found that alterations in individual PKC isoforms may play significant roles in the pathogenesis of HCC (40).

Multidrug resistance 1 (MDR1) is at the downstream of PKC. Overexpression of the MDR1 gene has been demonstrated in primary liver tumors and in some preneoplastic lesions (8, 40). In HepG2 clones with HBx gene transfection, HBx may transactivate the expression of the endogenous MDR1 gene (15). Although MDR1 transcription is regulated by PKCα and PKCθ in human breast carcinoma cells (19), PKCα, but not PKCβ I, PKCβ II or PKCγ, may play a role in multidrug resistance of gastric cancer cells SGC7901/VCR (20).

A previous study has found a significant association between the membranous-located PKCα and non-HCV infection in patients with HCC (43). To determine the role of PKCα in HCC, we further employed histoimmunopathologic techniques to investigate alteration of PKCα location and expression levels of phospho-MEK (mitogen-acrivated protein kinase) and MDR1 in hepatitis virus-related hepatocellular carcinoma biopsies. The expression levels of phospho-MEK and MDR1 became significantly higher in the specimens with membranous-located PKCα than in those with PKCα dispersed in the cytoplasm. These findings demonstrate the role of PKCα activation in hepatocarcinogenesis.

Materials and Methods

Materials

Antibodies against MDR1 were purchased from Zymed Laboratories Inc. (San Francisco, CA, USA) and those against phospho-MEK from Transduction Laboratories (Lexington, KY, USA). The polyclonal PKCα antibody was obtained from rabbits since day 42 after immunization as described in a previous study (41).

Specimen Collection

Liver biopsies were obtained from 19 patients in the Division of Hepatogastroenterology, Department of Internal Medicine, Changhua Christian Hospital. These patients were suspected to have a tumor in the liver based on clinical history, physical examination, the presence of α-fetoprotein and ultrasonography. An informed consent was obtained from each patient before the liver puncture. After collection, the specimens were immediately fixed in 4% formalin. Histopathological grading was then determined according to cell differentiation as well, moderately or poorly differentiated. The remaining portion of each specimen was employed for analysis of tumor markers by immunohistochemistry. In addition, HBs-Ag and anti-HCV were also detected. The tumor size was measured by ultrasonography, and TNM staging was determined by histopathology, ultrasonography, computerized axial tomography and angiography.
**Immunohistochemistry**

Formalin-fixed specimens were dehydrated through graded alcohol and were embedded in paraffin. Sections (3 µm) were prepared from the paraffin-embedded specimens and then deparaffinized in xylene and rehydrated through an alcohol series. The sections were then incubated with 3% H₂O₂ for 5 min. After washing with phosphate buffer saline (PBS), the sections were heat to boiling in EDTA solution (1 mM EDTA, 0.1% NP-40; pH 8.0) for 5 min for PKCα and MDR1 detection, or in citric acid solution (10 mM citric acid monohydrate; pH 6.0) for 15 min for phospho-MEK detection, in a microwave oven. This non-competitive inhibition procedure was repeated once after an interruption of 10 min.

After cooling for 20 min, the sections were washed three times in PBS for 5 min and then incubated in PBS with 3% normal bovine serum for 25 min. The sections were washed with PBS and incubated with purified polyclonal antibodies to PKCα (10 ng/ml PBS plus 0.2% BSA), phospho-MEK (1:50) and MDR1 (1:100) at room temperature for 1 h. After washing three times in PBS for 5 min, the sections were incubated with biotinylate-labeled goat anti-rabbit IgG (Sigma) at room temperature for 30 min. The sections were then washed with PBS and incubated with ABC regent (Avidin/Biotin kit, Vector Laboratories, Inc., Burlingame, CA, USA) conjugated with peroxidase at room temperature for 30 min. PKCα antigen staining was visualized by adding 3,3′-diaminobenzidine substrate (Sigma). The reaction was terminated by rinsing the sections in distilled water.

The sections were counterstained with Gill’s hematoxylin V (Mute pure Chemicals Ltd., Tokyo, Japan), dehydrated through graded alcohol, and cleared with xylene before mounting with Malinol (Mute Pure Chemicals Ltd., Tokyo, Japan). Immunoreactivity of phospho-MEK and MDR1 in the sections was examined by the BX40 system microscope (Olympus, Tokyo, Japan) with a CCD DII Camera (Olympus, Tokyo, Japan). Images were analyzed by the Image-Pro® Plus software (Media Cybernetics, Silver Spring, MD, USA). The tissues were classified as cytosolic type for those with PKCα deposited in the cytoplasm in more than 50% of the cells and the remaining ones were defined as membranous type.

**Statistical Analysis**

Levels of PKCα, phospho-MEK, and MDR1 were represented by the percentages of the measurements to the average of the adjacent non-cancerous (control) in the biopsies and expressed as means ± standard error. Categorical variables were analyzed by the Fisher exact test and continuous variables by the Mann-Whitney U test. P < 0.05 was considered to be statistically significant.

**Results**

**Clinical Characteristics**

The 19 patients, as described in the previous study (43), included 18 males and 1 female and aged from 33 to 81 years (61.7 ± 3.0 years). 7 patients had HBsAg alone, 8 had anti-HCV alone, and 1 had both HBsAg and Anti-HCV. Only 2 patient was negative for HBsAg and anti-HCV. TNM staging identified 1 T1, 4 T2, 9 T3, and 5 T4 lesions. The tumor size was 6.7 ± 1.3 cm. Histopathologic analysis of the tumors revealed 7 with well differentiated cells, 10 with moderately differentiated cells, and 2 with poorly differentiated cells.

**Immunohistological Findings**

![Image](image-url)

Fig. 1 shows the membranous (Fig. 1A) and cytosolic (Fig. 1B) locations of PKCα in HCC and the expression of phospho-MEK (Fig. 1, C and D) and MDR1 (Fig. 1, E and F) in the corresponding locations. In the specimens with PKCα on the membrane, the staining intensities of phospho-MEK (Fig. 1C) and MDR1 (Fig. 1E) were strong and homogeneous. However, the intensities were relatively low in specimens with cytosolic located PKCα (Fig. 1, D and E).

**PKCα Location and Expression of Phospho-MEK and MDR1**

Significantly higher levels of phospho-MEK and MDR1 expression were found in membranous type than those in cytosolic type (P < 0.05) (Table 1).

**Clinical Characteristics and Expression of Phospho-MEK and MDR1**

The expression of MDR1 was significantly higher in the patients with anti-HCV negative or T3 and T4 staging (P < 0.05). However, no significant associations was found between phospho-MEK and the clinical characteristics (P > 0.05) (Table 2).

**Discussion**

From our previous studies, we have found that the activity of the membrane-bound PKC is significantly decreased in cancerous human liver tissues compared with that of the adjacent normal tissues whereas no significant difference in the activity was
Expression of MEK and MDR1 in Human HCC

observed in the cytosolic fractions (6). Using Western blotting, we also determined that the level of membrane-bound PKCα in HCC tissues was significantly lower than that in the adjacent normal tissues (40). In Hep3B cells, we observed that PKC activity increases as an expression of increased proliferation of the cells in response to PMA at a low concentration (10 nM). Using immunocytochemistry, it has been observed that the activation of PKC by PMA takes the form of the translocation of PKC isoforms from cytosol to membrane or the nucleus (23). It has been reported that PKC is a target for general anesthetic action (37). Moreover, halothane may also induce down-regulation in membrane-associated PKC activity (21). In our recent study, we used immunohistochemistry to compare PKCα expression in liver biopsies and surgical specimens from patients with HCC and demonstrated the effects of general anesthetics on the expression of PKCα (41). The inconsistent findings in our previous studies

Fig. 1. Immunohistochemical analyses of protein kinase C alpha (PKCα) (A and B), phospho-MEK (C and D), and MDR1 (E and F) in the cancerous hepatic tissue of two patients with hepatocellular carcinoma (magnification, ×400). Specimens of membranous type are shown in A, C and E (patient no. 15) and those of cytosolic type in B, D, and F (patient no. 2).
on liver cancer may be due to the effects of anesthesia on the surgical specimens. Therefore, we used liver biopsies as the materials in this study and the results agree with our findings obtained from studying Hep3B cells.

In the previous study, we have found a significant association of the membranous type with non-HCV infection and the cytosolic type with HCV infection (43). It has been reported that nuclear translocation and enzymatic activity of the catalytic subunit of PKA may be inhibited by NS3, one of the proteins produced by HCV. This viral nonstructural protein may also inhibit TPA-induced redistribution of PKC \( \alpha \) or PKC \( \beta \) (4). These changes may lead to impairment in the functions of these kinases and, hence, the cytosolic type of PKC\( \alpha \) in the specimens with positive anti-HCV.

Among the PKC isoenzymes, PKC\( \alpha \) has been particularly identified as a determinant of expression of the MDR phenotype. MCF-7/ADR breast carcinoma cells, with acquired resistance against adriamycin, possess elevated levels of PKC\( \alpha \) and display the MDR phenotype (5). However, MDR1 induction in leukemia cells by TPA is completely unaffected by a MEK inhibitor. Moreover, an effective inhibitor of TPA-mediated p38 activation also fails to inhibit TPA-induced MDR1 mRNA expression. Although MDR1 induction by TPA may occur via a PKC-dependent mechanism, this change is independent of ERK, p38 or JNK pathways (36). In this study, we found that the expression of phospho-MEK and MDR1 was elevated in HCC biopsies with membranous-located PKC\( \alpha \), but there is no significant correlation between the expression of phospho-MEK and MDR1 (data not shown). These results are consistent with the findings of the research done on leukemia cells. Thus, although PKC\( \alpha \) is considered to be involves in human hepatoma cell proliferation, migration and

Table 1. Expression (% of control) of phospho-MEK and MDR1 in hepatocellular carcinoma with different PKC\( \alpha \) locations

<table>
<thead>
<tr>
<th>Location of PKC( \alpha )</th>
<th>No. of biopsies</th>
<th>Phospho-MEK</th>
<th>MDR1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membranous</td>
<td>11</td>
<td>176.0 ± 14.2( ^* ) †, ‡</td>
<td>142.0 ± 8.9( ^* )</td>
</tr>
<tr>
<td>Cytosolic</td>
<td>8</td>
<td>122.7 ± 13.2</td>
<td>110.5 ± 9.6</td>
</tr>
</tbody>
</table>

\( ^* \)Statistical analyses were performed by the Mann-Whitney U test. \( P < 0.05 \) was considered significant.  
\( ^\dagger \)Means ± SE.

Table 2. Association between the expression levels of phospho-MEK and MDR1 and the clinical characteristics of patients with hepatocellular carcinoma

<table>
<thead>
<tr>
<th>Clinical characteristic</th>
<th>Level( ^* ) of phospho-MEK high low</th>
<th>( P ^\dagger )</th>
<th>Level( ^* ) of MDR1 high low</th>
<th>( P ^\dagger )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( \leq 60 ) years</td>
<td>4</td>
<td>4</td>
<td>NS</td>
<td>4</td>
</tr>
<tr>
<td>&gt; 60 years</td>
<td>7</td>
<td>4</td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>HBs-Ag</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>6</td>
<td>2</td>
<td>NS</td>
<td>6</td>
</tr>
<tr>
<td>Negative</td>
<td>5</td>
<td>6</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Anti-HCV</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>3</td>
<td>7</td>
<td>( &lt; 0.05 )</td>
<td>3</td>
</tr>
<tr>
<td>Negative</td>
<td>8</td>
<td>1</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>TNM-staging</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1 and T2</td>
<td>2</td>
<td>3</td>
<td>NS</td>
<td>2</td>
</tr>
<tr>
<td>T3 and T4</td>
<td>9</td>
<td>5</td>
<td></td>
<td>9</td>
</tr>
<tr>
<td>Histopathological grading</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well differentiated</td>
<td>5</td>
<td>2</td>
<td>NS</td>
<td>5</td>
</tr>
<tr>
<td>Moderately or poor differentiated</td>
<td>6</td>
<td>6</td>
<td></td>
<td>6</td>
</tr>
</tbody>
</table>

\( ^* \)The expression of phospho-MEK, which was higher than the average of all patients, was designed as “high”; and which was lower than the average of all patients, was designed as “low”. The designation of MDR1 was the same as the phospho-MEK.  
\( ^\dagger \)Statistical analyses were performed by the Fisher exact test. \( P < 0.05 \) was considered significant.  NS, not significant.
invasion through the suppression of p38 MAPK signaling pathway (22, 42), the mechanism of the elevated MDR1 expression in HCC is still being discussed.

It has been reported that tamoxifen, an oral triphenylethylene anti-estrogen agent, inhibits the interaction of PKC with phospholipids leading to interference with the membrane binding of substrates to PKC (35). Moreover, this drug may act on the cytoplasmic membrane and, hence, inhibits PKCα translocation to the membrane (7). The effectiveness of this drug in the treatment of HCC has been questioned because of the inconsistent results of clinical trials in different parts of the world (29). Comparing clinical trials with different incidences of HBV and HCV infections, this drug was found to be effective in studies of specimens with a higher percentage of HBV infection (10, 17). Based on the results of this study, many of the patients with HCC of PKCα membranous type were positive for HBsAg. Moreover, in these patients, the expression of MDR1 was also found to be elevated as was the level of activation of PKCα. Whether administrating tamoxifen interferes with the activation of PKCα and the expression of MDR1 in HCC is still under discussion.

Acknowledgments

This work was supported by the grants from the National Science Council, Republic of China (NSC 92-2745-B-040-001 and NSC 92-2314-13-075A-001).

References


